Short Interest in OSR Holdings, Inc. (NASDAQ:OSRH) Rises By 101.1%

OSR Holdings, Inc. (NASDAQ:OSRH) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 1,094,583 shares, a growth of 101.1% from the December 31st total of 544,307 shares. Based on an average trading volume of 4,985,615 shares, the days-to-cover ratio is currently 0.2 days. Currently, 10.8% of the company’s stock are sold short. Currently, 10.8% of the company’s stock are sold short. Based on an average trading volume of 4,985,615 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP bought a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. Institutional investors and hedge funds own 55.30% of the company’s stock.

OSR Stock Performance

NASDAQ:OSRH traded down $0.06 during trading hours on Friday, reaching $0.58. 537,861 shares of the company were exchanged, compared to its average volume of 3,151,732. OSR has a 52-week low of $0.45 and a 52-week high of $11.84. The stock has a 50 day simple moving average of $0.66 and a 200 day simple moving average of $0.67.

OSR (NASDAQ:OSRH) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $0.63 million during the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised OSR to a “sell” rating in a research report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.